Lista de obras - María Reig - Dominio Público Uruguay

"New trials and results in systemic treatment of HCC".

artículo científico publicado en 2018

Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star.

artículo científico publicado en 2009

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.

artículo científico publicado en 2018

Approach of the patient with a liver mass

artículo científico publicado en 2012

Are alpha-fetoprotein and other markers useful in the diagnosis and prognosis of hepatocellular carcinoma?

artículo científico publicado en 2013

Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them.

artículo científico publicado en 2017

Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.

artículo científico publicado en 2009

Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers

artículo científico publicado en 2017

Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques

artículo científico

Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events.

artículo científico publicado en 2017

Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.

artículo científico publicado en 2018

Controversies in the management of hepatocellular carcinoma

scientific article published on 18 March 2019

Current strategy for staging and treatment: the BCLC update and future prospects.

artículo científico publicado en 2010

DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

artículo científico publicado en 2022

Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma

scientific article published on 01 February 2020

Does ramucirumab deserve a second chance for liver cancer?

artículo científico publicado en 2015

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib

artículo científico publicado en 2014

Early diagnosis of primary liver cancer: imaging versus genetics

artículo científico publicado en 2008

Evaluating the response to locoregional and systemic treatment for hepatocellular carcinoma

scientific article published on 06 July 2018

Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

artículo científico publicado en 2009

Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

artículo científico publicado en 2016

FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: Could a negative result be accepted as positive?

artículo científico publicado en 2014

Fe de errores de «Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica» [Gastroenterol Hepatol. 2018;41(5):328-349]

scientific article published on 01 August 2018

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents

scientific article published on 01 May 2019

Hepatocellular carcinoma

artículo científico publicado en 2018

If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?

artículo científico publicado en 2013

Insights into the success and failure of systemic therapy for hepatocellular carcinoma

artículo científico publicado en 2019

International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

artículo científico publicado en 2020

Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound

scientific article published on 01 June 2010

Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm.

artículo científico publicado en 2014

Lenvatinib: can a non-inferiority trial change clinical practice?

artículo científico publicado en 2018

Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply

artículo científico publicado en 2020

Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?

artículo científico publicado en 2017

Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US.

artículo científico publicado en 2015

Management of HCC

artículo científico publicado en 2012

Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.

artículo científico publicado en 2009

New Systemic Treatments in Advanced Hepatocellular Carcinoma

article

New drugs for the treatment of hepatocellular carcinoma.

artículo científico publicado en 2009

Non-invasive diagnosis of hepatocellular carcinoma ⩽2cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI

artículo científico publicado en 2012

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab

artículo científico publicado en 2020

Pattern of tumor progression in liver cancer: The missing partner in trial design.

artículo científico publicado en 2015

Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma

artículo científico publicado en 2019

Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials

artículo científico publicado en 2020

Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis.

artículo científico

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

artículo científico publicado en 2013

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

artículo científico publicado en 2019

Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma

artículo científico publicado en 2012

Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma

artículo científico publicado en 2010

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

artículo científico publicado en 2020

Reply

artículo científico publicado en 2015

Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing".

artículo científico publicado en 2016

Reply to: "The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut"

scientific article published on 13 December 2019

Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response"

artículo científico publicado en 2019

Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals

scientific article published on 28 August 2019

Should Patients With NAFLD/NASH Be Surveyed for HCC?

artículo científico publicado en 2019

Sorafenib for hepatocellular carcinoma: global validation.

artículo científico publicado en 2009

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

artículo científico publicado en 2016

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.

artículo científico publicado en 2012

Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib

artículo científico publicado en 2019

Systemic Treatment: Expecting Further Success

artículo científico publicado en 2015

Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST.

artículo científico publicado en 2014

Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success

artículo científico publicado en 2018

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond

artículo científico publicado en 2018

Systemic treatment

artículo científico

Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.

artículo científico publicado en 2016

The Search for an Effective Partner for Sorafenib: The Failure of Doxorubicin

artículo científico publicado en 2011

The calm before the storm: a report from the International Liver Cancer Association Congress 2015 - part 2.

artículo científico publicado en 2016

The calm before the storm: a report from the International Liver Cancer Association Congress 2015--part 1.

artículo científico publicado en 2016

The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma.

artículo científico publicado en 2017

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments.

artículo científico publicado en 2017

Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients

artículo científico publicado en 2019

Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules

scientific article published on 24 January 2019

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

article

Treatment of Hepatocellular Carcinoma with Radioembolization: Gathering Assumptions for Trial Design

artículo científico publicado en 2013

Treatment of Hepatocellular Carcinoma.

artículo científico publicado en 2016

Treatment of advanced hepatocellular carcinoma

artículo científico publicado en 2010

Treatment of early hepatocellular carcinoma: Towards personalized therapy

artículo científico publicado en 2010

Treatment of hepatocellular carcinoma.

artículo científico publicado en 2014

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.

artículo científico publicado en 2017

Twenty-four weeks therapy with peginterferon alfa-2a could be similar to 48 weeks therapy in patients with HBeAg positive chronic hepatitis B and good predictors of response: results of a pilot study

scientific article published on 01 December 2009

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

artículo científico publicado en 2016

Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma

artículo científico publicado en 2015

Lista de obras de María Reig

"New trials and results in systemic treatment of HCC".

Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star.

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.

Approach of the patient with a liver mass

Are alpha-fetoprotein and other markers useful in the diagnosis and prognosis of hepatocellular carcinoma?

Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them.

Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.

Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers

Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques

Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events.

Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.

Controversies in the management of hepatocellular carcinoma

Current strategy for staging and treatment: the BCLC update and future prospects.

DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma

Does ramucirumab deserve a second chance for liver cancer?

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib

Early diagnosis of primary liver cancer: imaging versus genetics

Evaluating the response to locoregional and systemic treatment for hepatocellular carcinoma

Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: Could a negative result be accepted as positive?

Fe de errores de «Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica» [Gastroenterol Hepatol. 2018;41(5):328-349]

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents

Hepatocellular carcinoma

If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?

Insights into the success and failure of systemic therapy for hepatocellular carcinoma

International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound

Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm.

Lenvatinib: can a non-inferiority trial change clinical practice?

Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply

Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?

Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US.

Management of HCC

Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.

New Systemic Treatments in Advanced Hepatocellular Carcinoma

New drugs for the treatment of hepatocellular carcinoma.

Non-invasive diagnosis of hepatocellular carcinoma ⩽2cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab

Pattern of tumor progression in liver cancer: The missing partner in trial design.

Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma

Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials

Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis.

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma

Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

Reply

Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing".

Reply to: "The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut"

Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response"

Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals

Should Patients With NAFLD/NASH Be Surveyed for HCC?

Sorafenib for hepatocellular carcinoma: global validation.

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.

Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib

Systemic Treatment: Expecting Further Success

Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST.

Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond

Systemic treatment

Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.

The Search for an Effective Partner for Sorafenib: The Failure of Doxorubicin

The calm before the storm: a report from the International Liver Cancer Association Congress 2015 - part 2.

The calm before the storm: a report from the International Liver Cancer Association Congress 2015--part 1.

The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma.

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments.

Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients

Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Treatment of Hepatocellular Carcinoma with Radioembolization: Gathering Assumptions for Trial Design

Treatment of Hepatocellular Carcinoma.

Treatment of advanced hepatocellular carcinoma

Treatment of early hepatocellular carcinoma: Towards personalized therapy

Treatment of hepatocellular carcinoma.

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.